Biotech Values

[DewDiligence]

My V-Pak estimate for 1Q15 is $350-450M (#msg-111336181), although I won’t be shocked if the figure is only $250M, due to slowness in clearing reimbursement for Medicaid and other public-payer patients.

Perhaps more important, I’m not expecting ABBV to provide more detailed V-Pak guidance for the full year 2015 than it already has with its statement of a $3B+ year-end annualized run rate. (I do expect more detailed full-year guidance after the 2Q15 results.)